Melt Pharmaceuticals (MELT) Announces Proposed IPO

Melt Pharmaceuticals (NASDAQ: MELT) has filed for a proposed IPO.

The analyst comments: "Melt is a clinical stage pharmaceutical company focused on the development and commercialization of proprietary non-opioid, non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient and in-office settings. We intend to seek regulatory approval through the FDA’s 505(b)(2) regulatory pathway for these proprietary, patented small-molecule product candidates, where possible. The core intellectual property we own is a patented series of combination non-opioid sedation drug formulations that we believe have multiple clinical applications for potential indications of use."

AEGIS CAPITAL CORP will serve as sole underwriter.

You May Also Be Interested In

• Trident Digital Tech Holdings (TDTH) Announces Downsized 1.8M ADS IPO at $5-$7/sh
• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• Tandy Leather Factory (TLF) Appoints Diana Saadeh-Jajeh to its Board